Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

11.34USD
27 Apr 2017
Change (% chg)

$0.13 (+1.16%)
Prev Close
$11.21
Open
$11.20
Day's High
$11.53
Day's Low
$11.20
Volume
52,089
Avg. Vol
241,795
52-wk High
$19.91
52-wk Low
$8.70

INSY.OQ

Chart for INSY.OQ

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $808.41
Shares Outstanding(Mil.): 72.11
Dividend: --
Yield (%): --

Financials

  INSY.OQ Industry Sector
P/E (TTM): 108.23 58.41 30.30
EPS (TTM): 0.10 -- --
ROI: 2.82 0.45 13.24
ROE: 2.91 6.31 14.40

BRIEF-Insys therapeutics accepts resignation of Santosh Vetticaden, interim CEO

* On April 11, 2017, Insys Therapeutics accepted resignation of Santosh Vetticaden, interim chief executive officer Source text for Eikon: Further company coverage:

Apr 17 2017

Insys' revenue plunges as Subsys prescriptions fall

Insys Therapeutics Inc on Monday reported a 41.6 percent decline in quarterly revenue, hurt by a fall in demand for Subsys, an opioid spray approved for managing pain in cancer patients.

Apr 03 2017

UPDATE 1-Insys' revenue plunges as Subsys prescriptions fall

April 3 Insys Therapeutics Inc on Monday reported a 41.6 percent decline in quarterly revenue, hurt by a fall in demand for Subsys, an opioid spray approved for managing pain in cancer patients.

Apr 03 2017

Insys Therapeutics' revenue falls 41.6 pct

April 3 Insys Therapeutics Inc on Monday reported a 41.6 percent decline in quarterly revenue, hurt by a fall in demand for its pain drug, Subsys.

Apr 03 2017

Insys to restate some financial statements

Insys Therapeutics Inc said on Friday that it will restate some financial statements due to the identification of certain errors.

Mar 31 2017

Insys to restate some financial statements

March 31 Insys Therapeutics Inc said on Friday that it will restate some financial statements due to the identification of certain errors.

Mar 31 2017

BRIEF-Insys Therapeutics to restate some financial statements

* Insys Therapeutics Inc-previously issued interim unaudited financial statements as of and for Sept 30, June 30, March 31, 2016 and 2015, should no longer be relied on

Mar 31 2017

BRIEF-Insys announces Saeed Motahari to become president and CEO

* Insys announces saeed motahari to become president and chief executive officer and member of the board of directors effective April 17, 2017

Mar 27 2017

BRIEF-Insys Therapeutics Drug Enforcement Agency issued an interim final rule

* Insys Therapeutics-drug enforcement agency issued interim final rule that would result in syndros being placed in schedule II of Controlled Substances Act

Mar 23 2017

BRIEF-Neopharm to pay annual dividend as 350 won/share for FY 2016

* Says it will pay annual cash dividend as 350 won/share for FY 2016, to shareholders of record on Dec. 31, 2016

Feb 16 2017

More From Around the Web

Earnings vs. Estimates